ENHERTU (fam-trastuzumab deruxtecan-nxki)
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS·HER2-POSITIVE CARCINOMA OF BREAST·+5
DAIICHI SANKYO,
Indication
HER2-Positive Solid Tumor
A HER2-positive solid tumor refers to any non-hematologic malignancy across diverse organ systems—including the breast, gastrointestinal tract, biliary tract, lung, and gynecologic organs—characterized by the abnormal overexpression of the human epidermal growth factor receptor 2 protein or amplification of the *ERBB2* gene. Read more about HER2-Positive Solid Tumor
1 drugs 1 manufacturers
Drugs that treat it
Common HER2-Positive Solid Tumor therapies.
Filter & compare in the drug finder →Opens the drug finder with HER2-Positive Solid Tumor preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonA HER2-positive solid tumor refers to any non-hematologic malignancy across diverse organ systems—including the breast, gastrointestinal tract, biliary tract, lung, and gynecologic organs—characterized by the abnormal overexpression of the human epidermal growth factor receptor 2 protein or amplification of the *ERBB2* gene.
In clinical practice and regulatory definitions, HER2 positivity is typically confirmed by high-level protein expression (immunohistochemistry [IHC] 3+) or gene amplification detected via in situ hybridization.
Pathophysiologically, the excessive density of this receptor tyrosine kinase triggers constitutive downstream intracellular signaling through the MAPK and PI3K/AKT pathways, resulting in uncontrolled cellular proliferation, survival, and heightened tumor aggressiveness.
- cancer.gov
A HER2-positive solid tumor refers to any non-hematologic malignancy across diverse organ systems—including the breast, gastrointestinal tract, biliary tract, lung, and gynecologic organs—characterized by the abnormal overexpression of the human epidermal growth factor receptor 2 protein or amplification of the *ERBB2* gene
- aacr.org
A HER2-positive solid tumor refers to any non-hematologic malignancy across diverse organ systems—including the breast, gastrointestinal tract, biliary tract, lung, and gynecologic organs—characterized by the abnormal overexpression of the human epidermal growth factor receptor 2 protein or amplification of the *ERBB2* gene
- cap.org
A HER2-positive solid tumor refers to any non-hematologic malignancy across diverse organ systems—including the breast, gastrointestinal tract, biliary tract, lung, and gynecologic organs—characterized by the abnormal overexpression of the human epidermal growth factor receptor 2 protein or amplification of the *ERBB2* gene In clinical practice and regulatory definitions, HER2 positivity is typically confirmed by high-level protein expression (immunohistochemistry [IHC] 3+) or gene amplification...
- enhertuhcp.com
In clinical practice and regulatory definitions, HER2 positivity is typically confirmed by high-level protein expression (immunohistochemistry [IHC] 3+) or gene amplification detected via in situ hybridization
- mdanderson.org
In clinical practice and regulatory definitions, HER2 positivity is typically confirmed by high-level protein expression (immunohistochemistry [IHC] 3+) or gene amplification detected via in situ hybridization
Personalize your experience
Follow HER2-Positive Solid Tumor and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.